Radioembolization in the Treatment of Unresectable Liver Tumors
- 1 April 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in American Journal of Clinical Oncology
- Vol. 35 (2), 167-177
- https://doi.org/10.1097/coc.0b013e3181f47923
Abstract
Radioembolization is a proven treatment to slow disease progression and improve survival in patients with colorectal cancer liver metastases and hepatocellular carcinoma. Accumulating evidence supports its use in metastases from neuroendocrine tumors and breast cancer. Cancers with radiobiologic profiles similar to those of colorectal and breast cancer, including melanoma, lung cancer, and nodular cholangiocarcinoma, are being studied as candidates for radioembolization. This treatment modality has also been shown to downsize hepatic tumors for potentially curative ablation in patients with breast, pancreatic, and colorectal cancer. Radioembolization using either yttrium-90 ((90)Y)-labeled resin or glass microspheres represents a promising therapy for liver-only or liver-predominant tumors in patients with 1 or more variables, including adequate or sufficient functional liver reserve, good performance status, and absence of other significant comorbidities. Therapeutic efficacy and safety can be best achieved by use of careful dosimetric techniques and treatment planning. Radioembolization could be considered after progression of liver metastases during treatment hiatus, at an early therapeutic line in tumors that respond poorly to chemotherapy, or in treatment-refractory disease.Keywords
This publication has 45 references indexed in Scilit:
- Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver MetastasesJournal of Clinical Oncology, 2009
- Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resectionsWorld Journal of Surgical Oncology, 2009
- A First Report of Radioembolization for Hepatic Metastases From Ocular MelanomaCancer Investigation, 2009
- Clinical Course of Breast Cancer Patients With Metastases Limited to the Liver Treated With ChemotherapyThe Cancer Journal, 2008
- Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumoursEuropean Journal of Surgical Oncology, 2007
- Concordant F-18 FDG PET and Y-90 Bremsstrahlung Scans Depict Selective Delivery of Y-90-Microspheres to Liver Tumors: Confirmation With HistopathologyClinical Nuclear Medicine, 2007
- Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratioJournal of Translational Medicine, 2007
- Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: Value of FDG PET versus computed tomographyNuclear Medicine Communications, 2007
- Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 womenBreast Cancer Research and Treatment, 2005
- Prognostic factors for patients with liver metastases from breast cancerBreast Cancer Research and Treatment, 2005